Ingredion shares closed at US$97.91 after a mixed few years for holders, and the bigger question now is whether that price lines up with the cash the business is expected to generate over time.
-
Over the past 5 years the stock has returned 25.9%. This puts real weight on whether that gain is grounded in the company's underlying cash flows or mainly in changing market sentiment.
-
The planned US$3.6b purchase of Tate & Lyle can reshape Ingredion's mix toward texture and health focused ingredients. This may influence future cash flow growth, capital needs and the timing of returns from the combined business.
-
What if you looked at Ingredion through its earnings instead? See why Ingredion's 10.4x P/E tells a different valuation story .
The issue now is whether Ingredion's current share price is adequately supported by the intrinsic value suggested by its Discounted Cash Flow (DCF) estimate based on those cash flows.
If you are weighing Ingredion against other reformulation themed opportunities, it can help to compare it with companies surfaced by our our screener containing 16 high quality undiscovered gems .
Is Ingredion Fairly Priced on Cash Flow?
The Discounted Cash Flow (DCF) model here uses Ingredion's own cash generation to frame what today's US$97.91 share price is paying for. On the latest twelve month view, the group produced about US$448.2 million of free cash flow, and the model assumes this level recovers toward US$778 million in 2024 before easing back into more muted, long run projections.
That pattern matters for Ingredion because it sketches a business expected to see a near term lift in cash generation rather than a long decline. The planned US$3.6b Tate & Lyle acquisition sits in the background of those estimates, since a larger mix of texture and health focused ingredients could change how steady those future cash flows feel. Because the Tate & Lyle deal is framed as a way to ride a reformulation boom, the stock trading broadly in line with the DCF output suggests investors are already pricing in a meaningful portion of that opportunity at US$97.91. Find out what Ingredion could be worth using our Discounted Cash Flow (DCF) estimate .
The Ingredion Narrative: What Would Justify Today's Price?
Narratives pick up where the Ingredion valuation puzzle leaves off. They spell out which combinations of future growth, profitability and earnings power would need to hold for the shares to look meaningfully higher or lower than today's price, and each one treats fair value as a thesis about how Ingredion's business might evolve over time so you can see how that idea holds up as new information comes through.
Community views on Ingredion split between those who see the Tate & Lyle deal as a swing factor on risk and those who treat it as a long term upgrade.
Bull case: 9% undervalued
"The acquisition of Tate & Lyle has the potential to transform Ingredion from a predominantly commodity-oriented starch and sweetener processor into a more global specialty ingredients platform..."
Discover why this Narrative puts Ingredion at 9% undervalued .
Bear case: 11% overvalued
"The proposed Tate & Lyle acquisition has also drawn scrutiny, with the size of the transaction and a softer demand backdrop seen as key sources of uncertainty for Ingredion..."
Explore why this Narrative puts Ingredion at 11% overvalued .
One more angle on Ingredion that could change the story
There is still a crucial piece missing for Ingredion, which is who is actually driving the decisions at the top and how their pay packets line up with your interests over the long haul. See who runs Ingredion and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include INGR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
